

ASX ANNOUNCEMENT

TRANSCRIPT OF CELLMID INVESTOR BRIEFING

SYDNEY, Friday, 29 July 2016: Cellmid Limited (ASX: CDY) held an investor briefing via a broadcasted telephone conference on Wednesday, 27th July 2016.

Cellmid CEO, Maria Halasz, provided an overview of the Company's operations across subsidiaries Lyramid, Kinera and Advangen, as well as an update on preliminary financial results and international business development activities for FY2016.

Ms Halasz reported an increase of 81% in total Company sales at around \$3.5 million for FY2016 compared with the same period last year (FY2015: \$1.94 million). With an R&D tax refund of \$1.1 million the Company is expected to book total revenue of \$4.64 million for the financial year which is a 60% increase from 2015.

Managing Director of Advangen Inc., Japan, Koichiro Koike, provided insights into the multiple distribution opportunities being explored in the Japanese and Asian markets and plans for FY2017. Japanese sales continued to strengthen in FY2016 exceeding sales targets at \$2.3 million revenue. Advangen Japan expects to report an operational profit for 2016.

Kerry Yates, Managing Director of Colour Collective, Cellmid's US distribution partner for évolis® dialled in from their headquarters in Dallas, Texas, to give an overview of the market and revenue potential for évolis® in the US.

Ms Halasz has answered audience questions on the Company's midkine diagnostic partnerships, private label FGF5 inhibitor products in Taiwan, and the évolis® concept store in Japan.

The transcript of the telephone conference can be accessed here:

[Transcript of CDY Investor Briefing Call 27 July 2016](#)

END

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programmes in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases. Through its wholly owned subsidiaries, Advangen Limited and Advangen Inc., Cellmid also develops and sells FGF5 inhibitor hair loss products. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been developing midkine, a growth factor, for hair loss utilising its anti-apoptotic effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic protecting cells from dying. It is this mechanism of action that is thought to be responsible for midkine's ability to regenerate hair growth in various models of the condition.